Tonix Pharmaceuticals Launches Pivotal MDD Study for TNX-102 SL
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
Source: Newsfilter
- Study Initiation: On June 29, 2026, Tonix Pharmaceuticals announced the enrollment of the first patient in the HORIZON study, evaluating TNX-102 SL (5.6 mg) as a first-line monotherapy for major depressive disorder (MDD), with approximately 360 patients expected to be recruited across 30 sites in the U.S., demonstrating the company's commitment to expanding its presence in mental health.
- Clinical Objectives: The primary endpoint of the study is the change from baseline in the MADRS total score at Week 6, aimed at validating the efficacy of TNX-102 SL in improving depressive symptoms and sleep quality, reflecting Tonix's focus on new therapies amid challenges with tolerability and adherence in existing treatments.
- Market Demand: With over 21 million adults in the U.S. experiencing a major depressive episode each year, there is an urgent need for new effective treatments; the development of TNX-102 SL not only addresses this market gap but also has the potential to improve patient quality of life and reduce suicide risk.
- Drug Characteristics: TNX-102 SL is a novel sublingual tablet formulation that enables rapid absorption and reduces the production of active metabolites, featuring a multifaceted mechanism of action targeting neuronal receptors that influence sleep quality, indicating promising applications in MDD and other related conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNXP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNXP
Wall Street analysts forecast TNXP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.710
Low
65.00
Averages
67.50
High
70.00
Current: 12.710
Low
65.00
Averages
67.50
High
70.00
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tonix Pharmaceuticals Launches Pivotal MDD Study for TNX-102 SL
- Study Initiation: On June 29, 2026, Tonix Pharmaceuticals announced the enrollment of the first patient in the HORIZON study, evaluating TNX-102 SL (5.6 mg) as a first-line monotherapy for major depressive disorder (MDD), with approximately 360 patients expected to be recruited across 30 sites in the U.S., demonstrating the company's commitment to expanding its presence in mental health.
- Clinical Objectives: The primary endpoint of the study is the change from baseline in the MADRS total score at Week 6, aimed at validating the efficacy of TNX-102 SL in improving depressive symptoms and sleep quality, reflecting Tonix's focus on new therapies amid challenges with tolerability and adherence in existing treatments.
- Market Demand: With over 21 million adults in the U.S. experiencing a major depressive episode each year, there is an urgent need for new effective treatments; the development of TNX-102 SL not only addresses this market gap but also has the potential to improve patient quality of life and reduce suicide risk.
- Drug Characteristics: TNX-102 SL is a novel sublingual tablet formulation that enables rapid absorption and reduces the production of active metabolites, featuring a multifaceted mechanism of action targeting neuronal receptors that influence sleep quality, indicating promising applications in MDD and other related conditions.
See More
Raymond James Initiates Strong Buy Ratings for Tonix and MapLight
- Strong Buy Ratings: Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT), assigning price targets of $26 and $46 per share respectively, with expectations that upcoming catalysts will drive stock price increases.
- FDA Meeting Outlook: Analyst Tiago Fauth noted that Tonix is set to meet with the FDA in Q3 2026 to discuss the Phase 2 trial design for its Lyme disease candidate TNX-4800, which could serve as an adoption-friendly seasonal prevention option for motivated risk groups, enhancing its market competitiveness.
- Commercial Update Anticipation: Fauth expects Tonix to release its first commercial update on Tonmya in Q2 2026, which is the first FDA-approved fibromyalgia therapy in over 15 years, projecting peak sales of $400M to $500M, thereby providing a supportive floor for TNXP shares.
- MapLight Catalyst: MapLight's ML-007C-MA, targeting schizophrenia and Alzheimer's disease psychosis, is expected to have its mid-stage trial results released in mid-August, with the analyst suggesting that this readout is skewed to the upside and could emerge as a significant value driver for the company.
See More
Tonmya Treatment Expands Coverage to 52 Million Americans
- Market Access Expansion: Tonix announced a second commercial payer agreement for Tonmya, adding access to approximately 17 million more insured Americans, which represents about 29% of the U.S. commercial insurance market, significantly enhancing the company's market share in chronic pain management.
- First FDA-Approved Drug: Tonmya is the first FDA-approved treatment for fibromyalgia in adults in over 15 years, designed for long-term management of chronic pain associated with the condition, particularly benefiting millions of women, marking a significant breakthrough in treatment options.
- Lyme Disease Treatment Progress: Tonix plans to have its Lyme disease drug TNX-4800 supply ready by early 2027 and intends to conduct a human challenge trial in 2028, demonstrating the company's potential in infectious disease research and possibly laying the groundwork for future revenue growth.
- Positive Investor Sentiment: Despite TNXP shares having fallen about 34% this year, investor sentiment on Stocktwits remains in the 'bullish' zone, indicating strong market interest and confidence in the updates regarding Tonmya, which could provide momentum for a stock rebound.
See More
Tonix Pharmaceuticals Presents Fibromyalgia Study Data at ASCP 2026
- Current Drug Usage: In the 2023-2024 study, 40.2% of 261,776 fibromyalgia patients with Commercial or Medicare Advantage insurance were prescribed at least one opioid, indicating a persistent reliance on opioids despite existing guidelines discouraging their use.
- Patient Demographics: The study revealed that the average age of fibromyalgia patients was 52.3 years, with 92.1% being female, and opioid use was highest among older age groups, reaching 43.1% in those aged 61-65, highlighting the urgent need for effective pain management in older patients.
- Impact of New Drug Launch: Tonix's TONMYA®, launched in 2025, is the first new fibromyalgia drug approved in the U.S. in over 15 years, aiming to provide effective non-opioid treatment options that could transform patient care and reduce opioid dependence.
- Significant Educational Need: The CEO of Tonix emphasized the gap between clinical practice and evidence-based recommendations, indicating an urgent need to educate healthcare providers about fibromyalgia and the availability of non-opioid medications to improve overall patient health outcomes.
See More
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Tonix Pharmaceuticals will participate in two investor conferences on May 19 and 20, 2026, led by CEO Dr. Seth Lederman, aimed at enhancing the company's visibility in the biotechnology sector.
- Conference Details: The RBC Capital Markets Global Healthcare Conference will take place in New York on May 19, while the G.P. Annual Virtual Healthcare Conference will be held online on May 20, expected to attract significant investor interest.
- Product Development Progress: Tonix's TONMYA® is the first new treatment for fibromyalgia in over 15 years, currently undergoing clinical trials to evaluate its potential in major depressive disorder and acute stress reactions, highlighting the company's strategic focus on addressing high unmet medical needs.
- Advancement of Immunology Programs: The company is advancing immunology projects such as TNX-4800, a monoclonal antibody for Lyme disease prevention, and TNX-1500, a CD154/CD40 ligand inhibitor for preventing kidney transplant rejection, indicating Tonix's diversified strategic positioning in the biopharmaceutical field.
See More
Strong First Quarter Performance for TONMYA Post-Launch
- Prescription Growth: In the first full quarter since the launch of TONMYA, 2,145 healthcare providers prescribed the medication, with 3,588 patients initiating treatment and approximately 5,400 prescriptions filled, indicating strong market acceptance and patient demand, which suggests potential market share growth in fibromyalgia treatment.
- Strategic Partnership Expansion: In May 2026, the company signed an agreement with a leading group purchasing organization, providing access to TONMYA for approximately 35 million U.S. commercial lives, enhancing patient accessibility and expected to drive sales growth and brand recognition.
- Clinical Research Plans: The company anticipates initiating an adaptive Phase 2 field study for TNX-4800, a novel monoclonal antibody for Lyme disease prevention, in the first half of 2027, pending FDA agreement, which could open new revenue streams if approved.
- Strong Financial Position: As of March 31, 2026, the company reported approximately $185.5 million in cash and cash equivalents, and despite an increase in operational expenses to about $42.3 million, the $22.6 million raised through market financing will support future R&D and market expansion plans, ensuring ongoing operational capability in the competitive biotechnology sector.
See More
Tonix Pharmaceuticals Launches Pivotal MDD Study for TNX-102 SL
- Study Initiation: On June 29, 2026, Tonix Pharmaceuticals announced the enrollment of the first patient in the HORIZON study, evaluating TNX-102 SL (5.6 mg) as a first-line monotherapy for major depressive disorder (MDD), with approximately 360 patients expected to be recruited across 30 sites in the U.S., demonstrating the company's commitment to expanding its presence in mental health.
- Clinical Objectives: The primary endpoint of the study is the change from baseline in the MADRS total score at Week 6, aimed at validating the efficacy of TNX-102 SL in improving depressive symptoms and sleep quality, reflecting Tonix's focus on new therapies amid challenges with tolerability and adherence in existing treatments.
- Market Demand: With over 21 million adults in the U.S. experiencing a major depressive episode each year, there is an urgent need for new effective treatments; the development of TNX-102 SL not only addresses this market gap but also has the potential to improve patient quality of life and reduce suicide risk.
- Drug Characteristics: TNX-102 SL is a novel sublingual tablet formulation that enables rapid absorption and reduces the production of active metabolites, featuring a multifaceted mechanism of action targeting neuronal receptors that influence sleep quality, indicating promising applications in MDD and other related conditions.
See More
Raymond James Initiates Strong Buy Ratings for Tonix and MapLight
- Strong Buy Ratings: Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT), assigning price targets of $26 and $46 per share respectively, with expectations that upcoming catalysts will drive stock price increases.
- FDA Meeting Outlook: Analyst Tiago Fauth noted that Tonix is set to meet with the FDA in Q3 2026 to discuss the Phase 2 trial design for its Lyme disease candidate TNX-4800, which could serve as an adoption-friendly seasonal prevention option for motivated risk groups, enhancing its market competitiveness.
- Commercial Update Anticipation: Fauth expects Tonix to release its first commercial update on Tonmya in Q2 2026, which is the first FDA-approved fibromyalgia therapy in over 15 years, projecting peak sales of $400M to $500M, thereby providing a supportive floor for TNXP shares.
- MapLight Catalyst: MapLight's ML-007C-MA, targeting schizophrenia and Alzheimer's disease psychosis, is expected to have its mid-stage trial results released in mid-August, with the analyst suggesting that this readout is skewed to the upside and could emerge as a significant value driver for the company.
See More
Tonmya Treatment Expands Coverage to 52 Million Americans
- Market Access Expansion: Tonix announced a second commercial payer agreement for Tonmya, adding access to approximately 17 million more insured Americans, which represents about 29% of the U.S. commercial insurance market, significantly enhancing the company's market share in chronic pain management.
- First FDA-Approved Drug: Tonmya is the first FDA-approved treatment for fibromyalgia in adults in over 15 years, designed for long-term management of chronic pain associated with the condition, particularly benefiting millions of women, marking a significant breakthrough in treatment options.
- Lyme Disease Treatment Progress: Tonix plans to have its Lyme disease drug TNX-4800 supply ready by early 2027 and intends to conduct a human challenge trial in 2028, demonstrating the company's potential in infectious disease research and possibly laying the groundwork for future revenue growth.
- Positive Investor Sentiment: Despite TNXP shares having fallen about 34% this year, investor sentiment on Stocktwits remains in the 'bullish' zone, indicating strong market interest and confidence in the updates regarding Tonmya, which could provide momentum for a stock rebound.
See More
Tonix Pharmaceuticals Presents Fibromyalgia Study Data at ASCP 2026
- Current Drug Usage: In the 2023-2024 study, 40.2% of 261,776 fibromyalgia patients with Commercial or Medicare Advantage insurance were prescribed at least one opioid, indicating a persistent reliance on opioids despite existing guidelines discouraging their use.
- Patient Demographics: The study revealed that the average age of fibromyalgia patients was 52.3 years, with 92.1% being female, and opioid use was highest among older age groups, reaching 43.1% in those aged 61-65, highlighting the urgent need for effective pain management in older patients.
- Impact of New Drug Launch: Tonix's TONMYA®, launched in 2025, is the first new fibromyalgia drug approved in the U.S. in over 15 years, aiming to provide effective non-opioid treatment options that could transform patient care and reduce opioid dependence.
- Significant Educational Need: The CEO of Tonix emphasized the gap between clinical practice and evidence-based recommendations, indicating an urgent need to educate healthcare providers about fibromyalgia and the availability of non-opioid medications to improve overall patient health outcomes.
See More
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Tonix Pharmaceuticals will participate in two investor conferences on May 19 and 20, 2026, led by CEO Dr. Seth Lederman, aimed at enhancing the company's visibility in the biotechnology sector.
- Conference Details: The RBC Capital Markets Global Healthcare Conference will take place in New York on May 19, while the G.P. Annual Virtual Healthcare Conference will be held online on May 20, expected to attract significant investor interest.
- Product Development Progress: Tonix's TONMYA® is the first new treatment for fibromyalgia in over 15 years, currently undergoing clinical trials to evaluate its potential in major depressive disorder and acute stress reactions, highlighting the company's strategic focus on addressing high unmet medical needs.
- Advancement of Immunology Programs: The company is advancing immunology projects such as TNX-4800, a monoclonal antibody for Lyme disease prevention, and TNX-1500, a CD154/CD40 ligand inhibitor for preventing kidney transplant rejection, indicating Tonix's diversified strategic positioning in the biopharmaceutical field.
See More
Strong First Quarter Performance for TONMYA Post-Launch
- Prescription Growth: In the first full quarter since the launch of TONMYA, 2,145 healthcare providers prescribed the medication, with 3,588 patients initiating treatment and approximately 5,400 prescriptions filled, indicating strong market acceptance and patient demand, which suggests potential market share growth in fibromyalgia treatment.
- Strategic Partnership Expansion: In May 2026, the company signed an agreement with a leading group purchasing organization, providing access to TONMYA for approximately 35 million U.S. commercial lives, enhancing patient accessibility and expected to drive sales growth and brand recognition.
- Clinical Research Plans: The company anticipates initiating an adaptive Phase 2 field study for TNX-4800, a novel monoclonal antibody for Lyme disease prevention, in the first half of 2027, pending FDA agreement, which could open new revenue streams if approved.
- Strong Financial Position: As of March 31, 2026, the company reported approximately $185.5 million in cash and cash equivalents, and despite an increase in operational expenses to about $42.3 million, the $22.6 million raised through market financing will support future R&D and market expansion plans, ensuring ongoing operational capability in the competitive biotechnology sector.
See More
